These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26725263)

  • 61. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia.
    Miyawaki S; Hatsumi N; Tamaki T; Naoe T; Ozawa K; Kitamura K; Karasuno T; Mitani K; Kodera Y; Yamagami T; Koga D
    Leuk Lymphoma; 2010 Oct; 51(10):1855-61. PubMed ID: 20849384
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia.
    Spassov BV; Stoimenov AS; Balatzenko GN; Genova ML; Peichev DB; Konstantinov SM
    Hematology; 2011 Jan; 16(1):37-42. PubMed ID: 21269566
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
    Xu J; Zhang Y; Hu J; Ren Y; Wang H
    Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
    [No Abstract]   [Full Text] [Related]  

  • 65. [Association of WT1 rs16754 polymorphism with clinical features and prognosis in patients with acute myeloid leukemia].
    Xu J; Li L; Li J; Chen Y; Wang HW
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):898-902. PubMed ID: 27801325
    [TBL] [Abstract][Full Text] [Related]  

  • 66. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.
    Galimberti S; Guerrini F; Carulli G; Fazzi R; Palumbo GA; Morabito F; Petrini M
    Eur J Haematol; 2004 Jan; 72(1):45-51. PubMed ID: 14962262
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
    Qin YZ; Jiang Q; Xu LP; Jiang H; Wang Y; Zhao XS; Li ZR; Lai YY; Liu YR; Zhang XH; Liu KY; Huang XJ
    Ann Hematol; 2019 Nov; 98(11):2551-2559. PubMed ID: 31493003
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.
    Shibasaki Y; Seki Y; Tanaka T; Miyakoshi S; Fuse K; Kozakai T; Kobayashi H; Ushiki T; Abe T; Yano T; Moriyama M; Kuroha T; Isahai N; Takizawa J; Narita M; Koyama S; Furukawa T; Sone H; Masuko M
    Leuk Res; 2015 Jun; 39(6):667-71. PubMed ID: 25890432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Zimmermann M; Balgobind BV; Arentsen-Peters ST; Alders M; Willasch A; Kaspers GJ; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    J Clin Oncol; 2010 Oct; 28(28):e523-6; author reply e527-e528. PubMed ID: 20644087
    [No Abstract]   [Full Text] [Related]  

  • 72. Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma.
    Li X; Wang S; Sitaram RT; Andersson C; Ljungberg B; Li A
    PLoS One; 2013; 8(3):e58396. PubMed ID: 23484026
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
    Kim HR; Shin JH; Lee JN; Lee EY
    Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy.
    Sato H; Kobayashi T; Kameoka Y; Teshima K; Watanabe A; Yamada M; Yamashita T; Noguchi S; Michisita Y; Fujishima N; Kuroki J; Takahashi N
    Int J Clin Oncol; 2024 Apr; 29(4):481-492. PubMed ID: 38334897
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
    Ahmed ZA; Shaikh MS; Moatter T
    J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
    Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
    Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.
    Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA
    Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Paschka P; Holland KB; Schwind S; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
    Blood; 2010 Aug; 116(5):788-92. PubMed ID: 20442368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.